Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BMO Capital Maintains Outperform on Nuvei, Lowers Price Target to C$90

BMO Capital Maintains Outperform on Nuvei, Lowers Price Target to C$90

BMO Capital analyst James Fotheringham maintains Nuvei (TSX:NVEI) with a Outperform and lowers the price target from C$93 to C$90.

byBenzinga Newsdesk

March 9, 2023

1 minute read

BMO Capital analyst James Fotheringham maintains Nuvei (TSX:NVEI) with a Outperform and lowers the price target from C$93 to C$90.

Ferrari Raises FY23 Guidance On Q2 Earnings Beat, Solid Order Book

By Shivani Kumaresan

August 2, 2:21 PM

Ferrari NV (NYSE: RACE) reported second-quarter FY23 sales growth of 14% year-on-year to $1.61 billion (€1.47 billion),

RACE

Salarius Pharmaceuticals Presents Compelling Data In Two SP-3164 Targeted Protein Degrader Posters At The American Association For Cancer Research Annual Meeting

By Benzinga Newsdesk

April 20, 8:47 AM

SP-3164 demonstrates compelling antitumor activity in animal models of follicular lymphoma and compelling antitumor activity in animal models of multiple myelomaPreclinical findings support the Company's planned clinical

SLRX

Analyst Ratings

Forecasting The Future: 4 Analyst Projections For Vtex

By Benzinga Insights

May 14, 11:01 AM

Throughout the last three months, 4 analysts have evaluated Vtex (NYSE:VTEX), offering a diverse set of opinions from…

VTEX

Analyst Ratings

The Latest Analyst Ratings for VIZIO Holding

By Benzinga Insights

June 29, 8:02 AM

VIZIO Holding (NYSE:VZIO) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

VZIO

BMO Capital Maintains Outperform on Nuvei, Lowers Price Target to C$90

Related Posts

Ferrari Raises FY23 Guidance On Q2 Earnings Beat, Solid Order Book

Salarius Pharmaceuticals Presents Compelling Data In Two SP-3164 Targeted Protein Degrader Posters At The American Association For Cancer Research Annual Meeting

Forecasting The Future: 4 Analyst Projections For Vtex

The Latest Analyst Ratings for VIZIO Holding